Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sodium-dependent phosphate transporter type 2b (NaPi-IIb)
- Target
- NaPi-IIb
- Molecular classification
- Transporter, Sodium-dependent phosphate cotransporter (SLC34A2 family)
01
Overview
Sodium-dependent phosphate transporter type IIb (NaPi-IIb, Npt2b, SLC34A2) is the principal transporter mediating active absorption of dietary phosphate in the small intestine. It operates via a sodium-dependent mechanism and is regulated by dietary phosphate levels and hormones such as vitamin D and FGF23. NaPi-IIb and related transporters are central to systemic phosphate homeostasis. Modulation of intestinal phosphate absorption is a key therapeutic strategy in chronic kidney disease to reduce the risk of hyperphosphatemia. Despite this, attempts to inhibit NaPi-IIb directly have not yet led to successful treatments, likely due to complex regulation and compensatory mechanisms
- Other names
- NaPi-IIbNpt2bSLC34A2intestinal sodium-dependent phosphate transportertype IIb phosphate cotransporter
02
Mechanism of action
Phosphate binders: Bind dietary phosphate in the GI lumen to prevent transporter-mediated absorption\nNaPi-IIb inhibitors: Block the active sodium-dependent transport of phosphate across enterocytes (ineffective in human trials to date)
03
Biological functions
Intestinal phosphate absorptionRegulation of systemic phosphate homeostasis
04
Disease associations
Chronic kidney disease (CKD; role in hyperphosphatemia)Phosphate metabolism disorders
05
Safety considerations
Hypophosphatemia (risk with excessive blockade of phosphate absorption)GI side effects from binders (constipation, bloating)Challenges in targeting transporters (species differences, compensatory mechanisms)
06
Interacting drugs
Phosphate binders (e.g., sevelamer, lanthanum carbonate, calcium carbonate; reduce intestinal phosphate absorption by binding dietary phosphate—not targeting the transporter directly)
1 more in the full profile.
07
Biomarkers
Serum phosphate levelsFibroblast growth factor 23 (FGF23)1,25-dihydroxyvitamin D (calcitriol) levels
Beyond the preview
Go deeper on Sodium-dependent phosphate transporter type 2b (NaPi-IIb).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sodium-dependent phosphate transporter type 2b (NaPi-IIb).